Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (51) 51
humans (47) 47
breast cancer (45) 45
index medicus (43) 43
female (39) 39
cancer (30) 30
breast neoplasms - pathology (22) 22
aged (21) 21
middle aged (21) 21
adult (19) 19
hematology, oncology and palliative medicine (19) 19
original research (18) 18
breast neoplasms - drug therapy (17) 17
chemotherapy (17) 17
care and treatment (13) 13
neoplasm staging (13) 13
trastuzumab (13) 13
aged, 80 and over (11) 11
analysis (11) 11
health aspects (11) 11
obstetrics & gynecology (11) 11
physics, applied (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
blasting (10) 10
breast neoplasms - therapy (10) 10
engineering elements and units (10) 10
general measures for producing and maintaining effectivefunctioning of machines or installations (10) 10
heating (10) 10
joints or fittings for pipes (10) 10
lighting (10) 10
means for thermal insulation in general (10) 10
mechanical engineering (10) 10
metastasis (10) 10
physics, condensed matter (10) 10
pipes (10) 10
plant science (10) 10
research (10) 10
supports for pipes, cables or protective tubing (10) 10
survival (10) 10
thermal insulation in general (10) 10
weapons (10) 10
open-label (9) 9
plant sciences (9) 9
therapy (9) 9
women (9) 9
biomarkers (8) 8
breast neoplasms - economics (8) 8
breast neoplasms - metabolism (8) 8
breast neoplasms - mortality (8) 8
diagnosis (8) 8
materials science, multidisciplinary (8) 8
mortality (8) 8
review (8) 8
1506 (7) 7
abridged index medicus (7) 7
ceramics (7) 7
developing countries (7) 7
disease-free survival (7) 7
hyperthermia (7) 7
male (7) 7
microbiology (7) 7
prognosis (7) 7
receptor, erbb-2 - metabolism (7) 7
surgery (7) 7
treatment (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
adjuvant chemotherapy (6) 6
antibodies, monoclonal, humanized - adverse effects (6) 6
breast (6) 6
breast neoplasms - surgery (6) 6
chemotherapy, adjuvant (6) 6
gene expression (6) 6
life sciences (6) 6
limited resources (6) 6
neoadjuvant therapy (6) 6
neuroscience (6) 6
neurosciences (6) 6
original research article (6) 6
paclitaxel (6) 6
physics, mathematical (6) 6
risk factors (6) 6
settore med/06 - oncologia medica (6) 6
spectroscopy (6) 6
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
cancer therapies (5) 5
carcinoma (5) 5
chemistry, physical (5) 5
developing countries - economics (5) 5
double-blind method (5) 5
genes (5) 5
genetic aspects (5) 5
medical research (5) 5
medicine & public health (5) 5
nanoparticles (5) 5
pathology (5) 5
pharmacy (5) 5
receptor (5) 5
resource allocation (5) 5
silica (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Haci İsmailin yemini
: hikâye ve efsaneler. [Yazan] E. Kövlief
by K'ovliev, Eniu
1968, 139
Book
Details down arrow
2. Full Text Breast Cancer Diagnosis by Surface-Enhanced Raman Scattering (SERS) of Urine
by Moisoiu, V and Socaciu, A and Stefancu, A and Iancu, SD and Boros, I and Alecsa, CD and Rachieriu, C and Chiorean, AR and Eniu, D and Leopold, N and Socaciu, C and Eniu, DT
APPLIED SCIENCES-BASEL, ISSN 2076-3417, 02/2019, Volume 9, Issue 4, p. 806
Background: There is an ongoing research for breast cancer diagnostic tools that are cheaper, more accurate and more convenient than mammography. Methods: In... 
LABEL-FREE | PHYSICS, APPLIED | SPECTROSCOPY | urine | MATERIALS SCIENCE, MULTIDISCIPLINARY | PROSTATE-CANCER | breast cancer | multivariate data analysis | cation SERS activation | surface-enhanced Raman scattering | CHEMISTRY, MULTIDISCIPLINARY | Urine | Raman spectra | Data analysis | Mortality | Principal components analysis | Nitrates | Breast cancer | Mammography | Uric acid | Multivariate analysis | Nanoparticles | Proteins | Medicine | Organic chemistry | Wavelengths | Lasers | Pharmacy | Spectrum analysis | Breast | Chemical composition | Prostate cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text 133INORAL TUMOUR THERAPY IN EMERGING COUNTRIES: SPECIAL PROBLEMS ENCOUNTERED
by Eniu, A
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv46 - iv46
Abstract Treating cancer in emerging countries poses many specific obstacles interfering with the correct management of patients. Important heterogeneity... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Shortage of Drugs: Solutions
by Eniu, Alexandru
The Breast, ISSN 0960-9776, 11/2017, Volume 36, pp. S28 - S29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text IN28 - Shortage of Drugs: Solutions
by Eniu, Alexandru
The Breast, ISSN 0960-9776, 11/2017, Volume 36, pp. S28 - S29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
by de Azambuja, Evandro, Dr and Holmes, Andrew P, PhD and Piccart-Gebhart, Martine, MD and Holmes, Eileen, PhD and Di Cosimo, Serena, MD and Swaby, Ramona F, MD and Untch, Michael, MD and Jackisch, Christian, MD and Lang, Istvan, MD and Smith, Ian, MD and Boyle, Frances, MBBS and Xu, Binghe, MD and Barrios, Carlos H, MD and Perez, Edith A, MD and Azim, Hatem A, MD and Kim, Sung-Bae, MD and Kuemmel, Sherko, MD and Huang, Chiun-Sheng, MD and Vuylsteke, Peter, MD and Hsieh, Ruey-Kuen, MD and Gorbunova, Vera, MD and Eniu, Alexandru, MD and Dreosti, Lydia, MD and Tavartkiladze, Natalia, MD and Gelber, Richard D, PhD and Eidtmann, Holger, MD and Baselga, José, MD
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Summary Background Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PREDICTS | WOMEN | THERAPY | EVENTS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | CHEMOTHERAPY PLUS TRASTUZUMAB | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Administration, Oral | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Neoplasm Staging | Trastuzumab | Antimitotic agents | Product development | Breast cancer | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The global burden of women's cancers: a grand challenge in global health
by Ginsburg, Ophira and Bray, Freddie and Coleman, Michel P and Vanderpuye, Verna and Eniu, Alexandru and Kotha, S Rani and Sarker, Malabika and Huong, Tran Thanh and Allemani, Claudia and Dvaladze, Allison and Gralow, Julie and Yeates, Karen and Taylor, Carolyn and Oomman, Nandini and Krishnan, Suneeta and Sullivan, Richard and Kombe, Dominista and Blas, Magaly M and Parham, Groesbeck and Kassami, Natasha and Conteh, Lesong
The Lancet, ISSN 0140-6736, 02/2017, Volume 389, Issue 10071, pp. 847 - 860
Every year, more than 2 million women worldwide are diagnosed with breast or cervical cancer, yet where a woman lives, her socioeconomic status, and agency... 
BREAST-CANCER | SYSTEMATIC ANALYSIS | INCIDENCE RATES | MEDICINE, GENERAL & INTERNAL | NEW-ZEALAND | INDIGENOUS PEOPLE | WHITE WOMEN | CERVICAL-CANCER | HUMAN-PAPILLOMAVIRUS | MATERNAL MORTALITY | AFRICAN-AMERICAN | Women | Palliative treatment | Epidemiology | Cervical cancer | Cancer | Low income groups | Human papillomavirus | Womens health | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text IN07 NEW DRUGS, NEW SIDE EFFECTS: ENDOCRINE SIDE EFFECTS
by Eniu, Alexandra
Breast, The, ISSN 0960-9776, 2015, Volume 24, pp. S23 - S24
Hematology, Oncology and Palliative Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
by Stebbing, Justin, Prof and Baranau, Yauheni, MD and Baryash, Valeriy, MD and Manikhas, Alexey, MD and Moiseyenko, Vladimir, Prof and Dzagnidze, Giorgi, MD and Zhavrid, Edvard, Prof and Boliukh, Dmytro, MD and Stroyakovskii, Daniil, MD and Pikiel, Joanna, MD and Eniu, Alexandru, MD and Komov, Dmitry, MD and Morar-Bolba, Gabriela, MD and Li, Rubi K, MD and Rusyn, Andriy, Prof and Lee, Sang Joon, PhD and Lee, Sung Young, MS and Esteva, Francisco J, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Structural properties of melt versus sol-gel derived yttrium aluminosilicate systems
by Eniu, D and Simon, S
Ceramics International, ISSN 0272-8842, 06/2018, Volume 44, Issue 8, pp. 9581 - 9584
The present study reports results regarding the structure of yttrium aluminosilicate systems of similar composition obtained by melting and sol-gel methods.... 
B. X-ray methods | D. Glass ceramics | D. Y2O3 | B. Spectroscopy | A. Calcination | D. Y | O
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text 197PUnderstanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians
by Eniu, A and Pop, L and Stoian, A and Dronca, E and Matei, R and Ligtenberg, M and Ouchene, H and Onisim, A and Rotaru, O and Eniu, R and Antone, N
Annals of Oncology, ISSN 0923-7534, 09/2017, Volume 28, Issue suppl_5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
by Zielinski, Christoph, Prof and Láng, István, Prof and Inbar, Moshe, Prof and Kahán, Zsuzsanna, Prof and Greil, Richard, Prof and Beslija, Semir, Prof and Stemmer, Salomon M, MD and Zvirbule, Zanete, MD and Steger, Günther G, MD and Melichar, Bohuslav, Prof and Pienkowski, Tadeusz, MD and Sirbu, Daniela, MD and Petruzelka, Luboš, Prof and Eniu, Alexandru, MD and Nisenbaum, Bella, MD and Dank, Magdalena, Prof and Anghel, Rodica, Prof and Messinger, Diethelm, MSc and Brodowicz, Thomas, MD and Turandot Investigators and TURANDOT investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1230 - 1239
Summary Background The randomised phase 3 TURANDOT trial compared two approved bevacizumab-containing regimens for HER2-negative metastatic breast cancer in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | THERAPY | ONCOLOGY | WEIGHT | CHEMOTHERAPY | Capecitabine - administration & dosage | Prognosis | Bevacizumab - administration & dosage | Follow-Up Studies | Neoplasm Recurrence, Local - metabolism | Humans | Receptor, ErbB-2 - metabolism | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Neoplasm Recurrence, Local - pathology | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quality of Life | Female | Aged | Neoplasm Staging | Paclitaxel - administration & dosage | Care and treatment | Breast cancer | Metastasis | Angiogenesis inhibitors | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Access to Affordable Breast Cancer Care in Eastern Europe
by Eniu, Alexandru and Antone, Nicoleta
Current Breast Cancer Reports, ISSN 1943-4588, 9/2018, Volume 10, Issue 3, pp. 170 - 178
The majority of Central and Eastern European (CEE) countries report inferior breast cancer survival rates compared with Western European countries. We review... 
Medicine & Public Health | Limited resources | Eastern Europe | Oncology | Internal Medicine | Breast cancer | Surgical Oncology | Radiotherapy | Palliative treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Changing global policy to deliver safe, equitable, and affordable care for women's cancers
by Ginsburg, Ophira and Badwe, Rajan and Boyle, Peter and Derricks, Gemma and Dare, Anna and Evans, Tim and Eniu, Alexandru and Jimenez, Jorge and Kutluk, Tezer and Lopes, Gilberto and Mohammed, Sulma I and Qiao, You-Lin and Rashid, Sabina Faiz and Summers, Diane and Sarfati, Diana and Temmerman, Marleen and Trimble, Edward L and Padela, Aasim I and Aggarwal, Ajay and Sullivan, Richard
The Lancet, ISSN 0140-6736, 02/2017, Volume 389, Issue 10071, pp. 871 - 880
Breast and cervical cancer are major threats to the health of women globally, particularly in low-income and middle-income countries. Radical progress to close... 
BREAST-CANCER | MORTALITY | AFRICA | MEDICINE, GENERAL & INTERNAL | UNIVERSAL HEALTH COVERAGE | DISEASE BURDEN | SCREENING PRACTICES | MIDDLE | HIGH-INCOME COUNTRIES | AMERICAN MUSLIMS | INDIA | Women | Health aspects | Epidemiology | Spyware | Cervical cancer | Public health | Cancer | Low income groups | Medical research | Immunization | Mortality | Equity | Radiation therapy | Sustainable development | Human papillomavirus | Maternal & child health | Womens health | Bibliometrics | Surgery | Registration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
by del Giglio, Auro and Eniu, Alexandru and Ganea-Motan, Doina and Topuzov, Eskender and Lubenau, Heinz
BMC Cancer, ISSN 1471-2407, 11/2008, Volume 8, Issue 1, pp. 332 - 332
Background: Recombinant granulocyte colony-stimulating factors (G-CSFs) such as Filgrastim are used to treat chemotherapy-induced neutropenia. We investigated... 
CELL LUNG-CANCER | COLONY-STIMULATING FACTOR | ONCOLOGY | PHASE-III | PLUS | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Recombinant Proteins | Filgrastim | Taxoids - therapeutic use | Granulocyte Colony-Stimulating Factor - pharmacokinetics | Adult | Female | Neutropenia - chemically induced | Taxoids - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Double-Blind Method | Neutrophils - drug effects | Treatment Outcome | Breast Neoplasms, Male - drug therapy | Granulocyte Colony-Stimulating Factor - therapeutic use | Breast Neoplasms - drug therapy | Neutropenia - drug therapy | Analysis of Variance | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Breast Neoplasms, Male - pathology | Neoplasm Staging | Doxorubicin - adverse effects | Complications and side effects | Chemotherapy | Breast cancer | Drug therapy | Methods | Risk factors | Neutropenia | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Evaluation of clinical outcomes of her2/neu positive breast cancer patients treated with adjuvant trastuzumab in two oncology centers from middle income coutries
by Perroud, H.A and Alasino, C.M and Eniu, A and Antone, N
Annals of Oncology, ISSN 0923-7534, 10/2016, Volume 27, Issue suppl_6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
by Schneeweiss, Andreas and Chia, Stephen and Hickish, Tamas and Harvey, Vernon and Eniu, Alexandru and Waldron-Lynch, Maeve and Eng-Wong, Jennifer and Kirk, Sarah and Cortés, Javier
European Journal of Cancer, ISSN 0959-8049, 01/2018, Volume 89, pp. 27 - 35
We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus... 
Neoadjuvant therapy | Pertuzumab | Clinical efficacy | Disease-free survival | Breast cancer | Safety | Cardiotoxicity | Trastuzumab | SURVIVAL | MULTICENTER | FOLLOW-UP | OPEN-LABEL | DOCETAXEL | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | THERAPY | ONCOLOGY | CLINICAL-TRIALS | ASSOCIATION | Anthracyclines - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Humans | Middle Aged | Ventricular Function, Left - drug effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Stroke Volume - drug effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Anthracyclines - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Heart - drug effects | Adult | Breast Neoplasms - mortality | Female | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Guideline implementation for breast healthcare in low-income and middle-income countries: Overview of the breast health global initiative Global Summit 2007
by Anderson, Benjamin O and Yip, Cheng-Har and Smith, Robert A and Shyyan, Roman and Sener, Stephen F and Eniu, Alexandru and Carlson, Robert W and Azavedo, Edward and Harford, Joe
Cancer, ISSN 0008-543X, 10/2008, Volume 113, Issue 8, pp. 2221 - 2243
Breast cancer outcomes in low- and middle-income countries (LMCs) correlate with the degree to which 1) cancers are detected at early stages, 2) newly detected... 
Screening | Low-income countries | Healthcare systems | Treatment | Resource allocation | Guideline | Breast cancer | Diagnosis | Early detection | Implementation | Process metrics | treatment | screening | implementation | breast cancer | diagnosis | process metrics | LIMITED-RESOURCE COUNTRIES | CHEMOTHERAPY | healthcare systems | STRATEGIES | TRIAL | MAMMOGRAPHY | WOMEN | resource allocation | THERAPY | ONCOLOGY | RECOMMENDATIONS | guideline | low-income countries | CANCER STATISTICS | early detection | RADIOTHERAPY | Breast Neoplasms - surgery | Risk Reduction Behavior | Developing Countries - economics | Early Detection of Cancer | Health | Humans | Income | Breast Neoplasms - prevention & control | Breast Neoplasms - therapy | Delivery of Health Care - standards | Time Factors | Breast | Female | Breast Neoplasms - diagnosis | Neoplasm Staging | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning
by Begum, Mursheda and Lewison, Grant and Jassem, Jacek and Mixich, Vlad and Cufer, Tanja and Nurgozhin, Talgat and Shabalkin, Pavel and Kutluk, Tezer and Voko, Zoltan and Radosavljevic, Davorin and Vrdoljiak, Eduard and Eniu, Alexandru and Walewski, Jan and Aggarwal, Ajay and Lawler, Mark and Sullivan, Richard
European Journal of Cancer, ISSN 0959-8049, 11/2018, Volume 104, pp. 127 - 136
Cancer research is an essential part of national cancer control programmes, and the emerging economies of Central and Eastern Europe (CEE) and the Russian... 
Central and Eastern Europe | Cancer policy | Cancer research | Bibliometrics | Framework programme | Central Asia | European Commission | MORTALITY | ONCOLOGY | IMPROVEMENT | CARE | Palliative treatment | Research | Analysis | Oncology, Experimental | Pancreatic cancer | Cancer | Medical research | Clinical trials | Oncology | Mapping | Cancer therapies | Disease control | Domains | Lungs | Outliers (statistics) | Surgery | Drug policy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Morphologic and molecular subtype status of individual tumor foci in multiple breast carcinoma. A study of 155 cases with analysis of 463 tumor foci
by Boros, Monica, MD and Ilyes, Agota, MD and Nechifor Boila, Adela, MD and Moldovan, Cosmin, MD, PhD and Eniu, Alexandru, MD, PhD and Stolnicu, Simona, MD PhD
Human Pathology, ISSN 0046-8177, 2014, Volume 45, Issue 2, pp. 409 - 416
Summary The aim of this study is to evaluate biomarker immunophenotypic heterogeneity between separate tumor foci of multiple breast carcinoma, its correlation... 
Pathology | Molecular status | Multiple breast carcinoma | Morphology | RECOMMENDATIONS | RECEPTOR | PATHOLOGY | CANCER | Immunohistochemistry | Neoplasms, Multiple Primary - metabolism | Humans | Middle Aged | Receptors, Estrogen - analysis | Neoplasms, Multiple Primary - pathology | Breast Neoplasms - metabolism | Receptors, Progesterone - analysis | Ki-67 Antigen - analysis | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Receptor, ErbB-2 - analysis | Breast cancer | Epidermal growth factor | Carcinoma | Progesterone | Analysis | Cancer | Lymphatic system | Chemotherapy | Histology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights